Cambridge Cognition Holdings PLC
LSE:COG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 5-Year Average (6.6), the stock would be worth GBX1 (97% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 230.1 | GBX35 |
0%
|
| 5-Year Average | 6.6 | GBX1 |
-97%
|
| Industry Average | 0 | GBX0.01 |
-100%
|
| Country Average | 0 | GBX0.01 |
-100%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Cambridge Cognition Holdings PLC
LSE:COG
|
16.3m GBP | 230.1 | -9.7 | |
| JP |
|
Medical Data Vision Co Ltd
TSE:3902
|
37.9T JPY | 86.2 | 227.5 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 28.3 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
25.9B USD | 13.8 | 28.5 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.1B AUD | 115.9 | 60.1 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 16.8 | 20.8 | |
| SE |
|
Sectra AB
STO:SECT B
|
49.7B SEK | 71.8 | 91.8 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.8B USD | 21.6 | 42.2 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.5B USD | 12.2 | 18.7 | |
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
261.1B INR | 97.8 | 40.3 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 66.3 | -328 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0.1 |
| Max | 1 344.9 |
Other Multiples
Cambridge Cognition Holdings PLC
Glance View
Cambridge Cognition Holdings Plc is a neuroscience digital health company, which engages in the development of digital health products to better understand, detect, and treat conditions affecting brain health. The firm develops and markets digital solutions to assess brain health for sale worldwide, principally in the United Kingdom, the United States and Europe. Its products include CANTAB Recruit, CANTAB Connect, Cognition Kit, Cognition eCOA, CANTAB Connect Research, CANTAB Mobile, CANTAB BrainHealth, CANTAB Insight and NeuroVocalix. Its services include neuroscience consultancy, study design, data analysis, study management, data management plan, reporting and interpretation and technical consultancy. Its CANTAB Connect offers digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas. Its Cognition Kit is a custom-designed digital health platform delivering wearable and smartphone applications for high frequency data collection to demonstrate treatment efficacy and increase the understanding of a disease and a patient's response to medication.
